Protandim is an "herbal supplement" based on extracts from milk thistle seeds, bacopa, ashwagandha
root, green tea leaves, and turmeric, and claimed by its marketers to reverse some of the effects of
aging. This claim has come under fire from reputable scientists and anti-aging researchers, and the
Protandim website has since modified its claims, admitting that
Protandim may provide no health benefits at all.

If you or a loved one are considering taking Protandim, please use the resources I have collected
here to make yourself more informed about this concoction and the company which is selling it. Don't
invest your money and health in anything unless your doctor has prescribed it to you, or you have
researched it thoroughly and found it to be worth the costs and risks.

If you are considering investing in LifeVantage, please use this site and others like it to research
the company and its products, and read the SEC's Penny
Stock Rules to ensure that you understand the risks: "Penny stocks may trade infrequently, which
means that it may be difficult to sell penny stock shares once you own them. Because it may be difficult
to find quotations for certain penny stocks, they may be impossible to accurately price. Investors
in penny stocks should be prepared for the possibility that they may lose their whole investment."

LifeVantage switched from a retail sales model to a
multi-level marketing (MLM) model.
If you are considering becoming involved in marketing and distributing Protandim, please be sure that
you understand multi-level marketing and are convinced that it is worth the costs and risks to yourself
and your family.

2016/1/5 Update: I've started getting calls again asking for me to update this page, so
I'll be doing just that for the next few days as time allows. Thanks for your patience!

Milk thistle extract[silybum marianum] - seeds
Warnings: "Side effects from milk thistle are rare and are limited mainly to digestive disturbances. The safety of
milk thistle for pregnant or nursing women, children, and people with severe kidney disease has not been established.
Milk thistle may reduce the effectiveness of oral contraceptives. One constituent of milk thistle can inhibit an enzyme
called beta-glucuronidase, which is involved in the activity of drugs such as oral contraceptives."

Bacopa extract[bacopa monniera] - aerial parts
Warnings: "Bacopa is said to be toxic at doses given .05 mg per kg of body weight."

Ashwagandha[withania somnifera] - roots
Warnings: "[Withania somnifera] is a member of the solanaceae or nightshade family so it can be extremely toxic.
It is recommended you purchase safe regulated product if you are not an experienced herbalist. Follow the recommended
dosage for that specific product. Do not use if pregnant or lactating due to its abortifacient effect. Use only under
physician or practitioner advisement."

Lifeline Nutraceuticals Corp. and Ceremedix, Inc. announce that LNC has exclusive, worldwide rights to market CMX-1152 "under a yet-to-be-determined brand name," beginning in the second quarter of 2004.

LTI CFO William Kutney requests an extension to file Form 10-KSB, because LTI "has not yet made final decisions concerning the accounting treatment of a number of matters" involving their huge financial loss during fiscal year 2005.

LTI announces the appointment of Stephen K. Onody as CEO and Board member effective 11/28/2005, at a pay rate of $280,000 a year plus bonuses and stock options. Brenda March will stay on through the transition.

LTI announces a loss of $571,044 on $1.7 million in revenues for the quarter ending 12/31/2005, down from a $80,314 profit on $2.9 million in revenues for the previous quarter. LTI reveals that it makes a 79-83% profit on each bottle of Protandim sold.

LTI issues a press release detailing their $670,911 loss in Q3 2006, and holds a conference call to discuss the results with investors. During the call, Stephen K. Onody announces plans to change the company name to Lifevantage.

Dr. Larry Gold resigns from the Board of Directors, stating that his "substantial experience in biotech and drug development has not been useful to Lifevantage."

12/21

James J. Krejci is appointed as CEO of Lifevantage Corporation, with an annual salary of $185,000 and a "discretionary bonus," as well as one million shares of the Company's common stock for 61¢ per share. 250,000 of Mr. Krejci's options will vest each December 21, from 2006 until 2009.

Lifevantage announces that Protandim will be featured on "Colorado & Company" (live), a magazine-style show on Denver NBC affiliate KUSA-TV, on Wednesday, October 24, 2007, some time between 10am and 11am MT.

10/12

Lifevantage submits its annual report indicating a FY2007 loss of $3,693,578 versus a loss of $2,734,501 in FY2006. The single included graph, which identifies its source as "National Business Journal, www.nutritionbussioness.com" is actually taken from the Nutrition Business Journal (www.nutritionbusiness.com).

Lifevantage reports to the SEC that it would be be "unable to file its Form 10-QSB [quarterly report] within the prescribed time period" due to "technical issues" linked to its recent private offering.

Lifevantage announces that Protandim will be featured on newsmagazine-style direct marketing television shows in nine local markets nationwide between October 24 and December 14.

11/30

Lifevantage presents a presentation of company history and future plans at its annual stockholders meeting. The presentation includes a bar chart which appears to claim induction of a ~19-fold increase in the expression of the antioxidative gene ag HO-1 mRNA/ng rRNA in human brain-derived cells.

Lifevantage submits an amendment to their submitted 8-K indicating that "there were no disagreements with GH&B on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure which, if not resolved to the satisfaction of GH&B, would have caused GH&B to make reference to the subject matter of the disagreement in connection with its report."

BUYINS.NET announces that LifeVantage has been added to the NASDAQ, AMEX and NYSE naked short threshold list: "With 24.77 million shares outstanding and 6,500 shares declared short as of January 2009, there is a failure to deliver in shares of LFVN. According to quarterly data provided by the SEC, there were still 308,013 shares of LFVN that were failing-to-deliver as of May 6, 2008."

5/5

BUYINS.NET announces that LifeVantage has been removed from the NASDAQ, AMEX and NYSE naked short threshold list.

5/15

BUYINS.NET announces that LifeVantage has been re-added to the NASDAQ, AMEX and NYSE naked short threshold list: "With 24.77 million shares outstanding and 40,500 shares declared short as of April 2009, there is a failure to deliver in shares of LFVN. According to quarterly data provided by the SEC, there were still 308,013 shares of LFVN that were failing-to-deliver as of May 6, 2008."

5/15

After Friday market close, LifeVantage submits its quarterly report to the SEC. The report details a net loss of $3,100,332 for the quarter compared to a net loss of $604,656 for the same quarter in 2008.

6/3

BUYINS.NET announces that LifeVantage has been removed from the NASDAQ, AMEX and NYSE naked short threshold list.

6/3

LifeVantage announces that its distributors can how buy samples of its TrueScience™ skin cream product.

LifeVantage announces the appointment of Kirby Zenger as Chief Operating Officer effective June 9, with an annual salary of $215,000.

6/16

LifeVantage announces that Brad Amman resigned as Chief Financial Officer effective June 9, and was appointed VP of Finance.

6/16

LifeVantage announces its TrueScience™ skin cream product at a multi-level marketing event in San Diego.

7/27

LifeVantage announces anticipated (unaudited) net revenue of approximately $1.6M for the quarter ended June 30, 2009 (an increase of about 150% over the previous quarter). The announcement attributes the increase to their new multi-level marketing program.

LifeVantage announces that the USPTO has granted the company its third patent based on Protandim and Protandim-related preparations.

9/28

LifeVantage reports a net loss of approximately $9,114,634 for fiscal year 2009, more than quadruple the $2,054,439 net loss for fiscal year 2008.

The Protandim Watch page was last updated on 8/5/2009.
Please call Tony Campbell at 615.852.8669 with corrections and updates.
I have no current or past affiliation with any of the companies listed on this page.